clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Díaz F et al. [Cat-scratch disease. A report of 4 cases and a review of the literature]. 1997 Rev Clin Esp pmid:9102668
Matsuoka N et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. 1996 Clin. Exp. Immunol. pmid:9099936
Klapper SR et al. Atypical mycobacterial infection of the orbit. 1995 Ophthalmology pmid:9097803
Hoogkamp-Korstanje JA et al. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. 1997 J. Antimicrob. Chemother. pmid:9096192
Gui GP et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. 1997 J. Antimicrob. Chemother. pmid:9096189
Driscoll MS and Tyring SK Development of resistance to clarithromycin after treatment of cutaneous Mycobacterium chelonae infection. 1997 J. Am. Acad. Dermatol. pmid:9091495
Gotoh A et al. Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. 1997 Microbiol. Immunol. pmid:9087962
Konishi T and Nakao M Antibiotic treatment in mice infected with Japanese Borrelia garinii: efficacy of ceftriaxone for eradicating the infection induced by Ixodes persulcatus tick bites. 1997 Microbiol. Immunol. pmid:9087959
al-Humayyd MS Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat. 1997 Mar-Apr Chemotherapy pmid:9084915
Reed PI and Johnston BJ Treatment of Helicobacter pylori infection. 1997 Biomed. Pharmacother. pmid:9084725
Labenz J [Helicobacter pylori eradication: finally clarity]. 1996 Leber Magen Darm pmid:9082109
Fujii K et al. Multiple primary Mycobacterium avium infection of the skin. 1997 Int. J. Dermatol. pmid:9071619
Weiss I et al. Serotyping and susceptibility to macrolides and other antimicrobial drugs of Streptococcus pyogenes isolated from patients with invasive diseases in southern Israel. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9063669
García-de-Lomas J et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolated from pediatric carriers in Spain. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9063666
Moayyedi P et al. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. 1997 J. Gastroenterol. pmid:9058291
Stone GG et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9056021
Roche B et al. Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi. 1997 Rev Rhum Engl Ed pmid:9051864
Erah PO et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. 1997 J. Antimicrob. Chemother. pmid:9044021
Labenz J et al. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. 1997 Aliment. Pharmacol. Ther. pmid:9042979
Labenz J et al. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. 1997 Aliment. Pharmacol. Ther. pmid:9042978
Axon AT et al. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9042977
Brady RC et al. Facial sporotrichoid infection with Mycobacterium marinum. 1997 J. Pediatr. pmid:9042142
Lerang F et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? 1997 Am. J. Gastroenterol. pmid:9040200
Dohil R et al. Effective 2-wk therapy for Helicobacter pylori disease in children. 1997 Am. J. Gastroenterol. pmid:9040199
Dautzenberg B et al. A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections. 1997 Jan-Feb Infection pmid:9039532
Kelleher P et al. Uveitis associated with rifabutin and macrolide therapy for Mycobacterium avium intracellulare infection in AIDS patients. 1996 Genitourin Med pmid:9038637
Yamamoto M et al. [The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection]. 1997 Kekkaku pmid:9038009
Engelhardt E et al. [Postoperative infection with Mycobacterium chelonae]. 1996 Hautarzt pmid:9036143
Burucoa C et al. Western blot monitoring of disseminated Nocardia nova infection treated with clarithromycin, imipenem, and surgical drainage. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9031879
Alarcón T et al. In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9031877
Macías J et al. Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. 1997 AIDS pmid:9030376
Wang XM et al. [Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy]. 1997 Nihon Shokakibyo Gakkai Zasshi pmid:9028149
Flisch CW et al. [A case of arthritis of the wrist caused by Mycobacterium marinum. Review of the literature]. 1996 Ann Chir Main Memb Super pmid:9026056
Berg-Candolfi M and Candolfi E Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection. 1996 Int. J. Parasitol. pmid:9024879
Paar D et al. Life-threatening interaction between clarithromycin and disopyramide. 1997 Lancet pmid:9024381
Knothe H [Short-term therapy of acute respiratory and ORL infections with Clarithromycin]. 1992 Z Gesamte Inn Med pmid:9022402
Banerjee DK et al. Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. 1997 Antimicrob. Agents Chemother. pmid:9021187
Walzer PD et al. Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. 1997 Antimicrob. Agents Chemother. pmid:9021174
Phull PS et al. Lansoprazole plus clarithromycin: evaluation of a new dual therapy for Helicobacter pylori eradication. 1996 Oct-Nov Br J Clin Pract pmid:9015906
Drouet M et al. [Unusual clinical form of amoxicillin allergy]. 1996 Allerg Immunol (Paris) pmid:9011169
Tursi A et al. Evaluation of the efficacy and tolerability of four different therapeutic regimens for the Helicobacter pylori eradication. 1996 Panminerva Med pmid:9009677
Bock H and Mares A [Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia]. 1996 Leber Magen Darm pmid:9005302
Shortridge VD et al. Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism. 1997 J. Clin. Microbiol. pmid:9003618
Gan VN et al. Penetration of clarithromycin into middle ear fluid of children with acute otitis media. 1997 Pediatr. Infect. Dis. J. pmid:9002099
Yanagihara K et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. 1997 Am. J. Respir. Crit. Care Med. pmid:9001333
Tanaka E [Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (2) Multi-drug chemotherapy for initial cases on trial]. 1996 Kekkaku pmid:8999140
Sakatani M [Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (1) Continuous positive cases (failure of the initial chemotherapy)]. 1996 Kekkaku pmid:8999139
Tsuyuguchi K [In vitro anti-MAC activities of new quinolones in focus (1)]. 1996 Kekkaku pmid:8999136
Tomioka H et al. [Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones]. 1996 Kekkaku pmid:8999135
van Zwet AA et al. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:8997557